• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TEMOZOLOMIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • TEMOZOLOMIDE chembl:CHEMBL810 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    SCH-52365
    CCRG-81045
    M&B-39831
    TEMODAL
    TEMOZOLOMIDE
    M-39831
    NSC-362856
    TEMODAR
    TEMOMEDAC
    TEMODAL®
    NSC 362856
    3-METHYL-4-OXO-3,4-DIHYDROIMIDAZO(5,1-D)(1,2,3,5)TETRAZINE-8-CARBOXAMIDE
    3,4-DIHYDRO-3-METHYL-4-OXOIMIDAZO(5,1-D)-AS-TETRAZINE-8-CARBOXAMIDE
    MB 39831
    CCRG 81045
    TÉMOZOLOMIDE
    3,4-DIHYDRO-3-METHYL-4-OXOIMIDAZO(5,1-D)-1,2,3,5-TETRAZINE-8-CARBOXAMIDE
    TEMOZOLOMID
    M & B 39831
    TEMODAR®
    BRN 5547136
    TEMOZOLOMIDUM
    TEMOZOLODIDA
    TEMOZOLOMIDA
    METHAZOLASTONE
    M&B 39831
    8-CARBAMOYL-3-METHYLIMIDAZO(5,1-D)-1,2,3,5-TETRAZIN-4(3H)-ONE
    TMZ
    SCH 52365
    CCRIS 8996
    rxcui:37776
    drugbank:00853
    pubchem.compound:5394
    chembl:CHEMBL810
    chemidplus:85622-93-1

    Drug Info:

    (2 More Sources)

    Publications:

    Yip et al., 2009, MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance., Clin. Cancer Res.
    Cahill et al., 2007, Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment., Clin. Cancer Res.
    Peasland et al., 2011, Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines., Br. J. Cancer
    Wang X et al., 2014, Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide., Ann Surg Oncol
    Trivedi et al., 2005, The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death., Cancer Res.
    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
    Watanabe et al., 2011, O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma., Brain Tumor Pathol
    Kreth et al., 2011, O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation., PLoS ONE
    Chinot et al., 2007, Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide., J. Clin. Oncol.
    Rapkins et al., 2015, The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide., Neuro-oncology
    Hegi et al., 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma., N. Engl. J. Med.
    Barvaux et al., 2004, Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase., Mol. Cancer Ther.
    Herrlinger U et al., 2019, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial., Lancet
    Lee et al., 2015, A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients., Clin. Cancer Res.
    Eich et al., 2013, Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide., Mol. Cancer Ther.
    Valiakhmetova A et al., 2020, Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response., Oncologist
    Lewis et al., 2005, A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF., Cancer Invest.
    de Gast et al., 2003, Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma., Br. J. Cancer
    Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.
    Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science
    Malmström A et al., 2020, ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide., Pharmacogenomics J
    Phillips et al., 2016, ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope., Mol. Cancer Ther.
    Kovacs et al., 2007, Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings., Hum. Pathol.
    Xu et al., 2016, Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial., Clin. Cancer Res.
    Wiestler et al., 2013, ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis., Acta Neuropathol.
    Tang SW et al., 2015, SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma., Clin Cancer Res
    Lok BH et al., 2017, PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer., Clin Cancer Res
  • TEMOZOLOMIDE   MSH6

    Interaction Score: 6.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type glioblastoma multiforme
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    19584161 17404084


    Sources:
    JAX-CKB NCI

  • TEMOZOLOMIDE   SLFN11

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25779942 27440269


    Sources:
    CIViC

  • TEMOZOLOMIDE   MGMT

    Interaction Score: 1.99

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24444404 21331613 21365007 17442989 25910840 15758010 15486188 30782343


    Sources:
    NCI CIViC PharmGKB

  • TEMOZOLOMIDE   H2AX

    Interaction Score: 1.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16024643


    Sources:
    NCI

  • TEMOZOLOMIDE   STAG2

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Olaparib + Temozolomide
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    24356817 21852505


    Sources:
    JAX-CKB

  • TEMOZOLOMIDE   ATRX

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23904111


    Sources:
    CIViC

  • TEMOZOLOMIDE   NOTCH1

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Radiotherapy + RO4929097 + Temozolomide
    Indication/Tumor Type glioblastoma multiforme
    Response Type sensitive

    PMIDs:
    27154916


    Sources:
    JAX-CKB

  • TEMOZOLOMIDE   BRCA2

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    32043779


    Sources:
    CIViC

  • TEMOZOLOMIDE   CSF2

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16100942 12610499


    Sources:
    NCI

  • TEMOZOLOMIDE   PRL

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17056093


    Sources:
    NCI

  • TEMOZOLOMIDE   HDAC4

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24444404


    Sources:
    PharmGKB

  • TEMOZOLOMIDE   ATM

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23960094


    Sources:
    CIViC

  • TEMOZOLOMIDE   PTEN

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Vandetanib + Temozolomide
    Indication/Tumor Type glioblastoma multiforme
    Response Type no benefit

    PMIDs:
    25910950


    Sources:
    JAX-CKB

  • TEMOZOLOMIDE   EGFR

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy ABT-414 + Temozolomide + Radiotherapy
    Indication/Tumor Type glioblastoma multiforme
    Response Type predicted – sensitive

    PMIDs:
    25910950 26846818


    Sources:
    JAX-CKB

  • TEMOZOLOMIDE   TP53

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type predicted – sensitive

    PMIDs:
    21730979 24248532


    Sources:
    JAX-CKB CIViC

  • TEMOZOLOMIDE   BRCA1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Talazoparib + Temozolomide
    Indication/Tumor Type ovarian cancer
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • TEMOZOLOMIDE   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31624332


    Sources:
    PharmGKB

  • TEMOZOLOMIDE   IDH1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type sensitive

    PMIDs:
    25910950


    Sources:
    JAX-CKB

  • NCI: TEMOZOLOMIDE

    • Version: 14-September-2017

    Alternate Names:
    C1244 NCI drug code

    Drug Info:

    Publications:
    de Gast et al., 2003, Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma., Br. J. Cancer
    Lewis et al., 2005, A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF., Cancer Invest.
    Trivedi et al., 2005, The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death., Cancer Res.

  • PharmGKB: temozolomide

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Malmström A et al., 2020, ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide., Pharmacogenomics J
    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics

  • JAX-CKB: Temozolomide

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Lee et al., 2015, A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients., Clin. Cancer Res.
    Solomon et al., 2011, Mutational inactivation of STAG2 causes aneuploidy in human cancer., Science
    Bailey et al., 2014, Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition., Mol. Cancer Ther.

  • CIViC: TEMOZOLOMIDE

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Herrlinger U et al., 2019, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial., Lancet
    Rapkins et al., 2015, The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide., Neuro-oncology
    Hegi et al., 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma., N. Engl. J. Med.

  • TTD: Temozolomide

    • Version: 2020.06.01

    Alternate Names:
    D0C8EU TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL810

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21